Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease

NCT04540497 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04540497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04540497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 4, 2020
Completion date
October 31, 2028
Enrollment
135 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

igg4 related disease